Earlier Risk Detection

Advances in genetics, imaging, biomarkers, and psychosocial health are creating new opportunities to identify cardiovascular risk earlier and more precisely. To explore how these emerging tools can improve prevention, the PRIME-Heart Initiative convened its inaugural Roundtable, bringing together experts from across disciplines to discuss strategies for earlier cardiovascular risk detection and intervention.

Explore the Roundtable materials, key takeaways, and insights that will help inform future clinical guidance and resources aimed at improving lifelong cardiovascular health.

• Advanced Cardiovascular Risk Detection for the Critical Decades Roundtable
• Key Takeaways

← Back

The PRIME-Heart Initiative is supported by:
Amgen, AstraZeneca, Boehringer Ingelheim, HeartFlow, Novartis, Novo Nordisk